Company · founded 2006
Cerulean Pharma (United States)
Cambridge, United States
- Citations, last 5 years
- 1
- Works, last 5 years
- 3
- h-index
- 52
- Scientists listed
- 0
- Grants since 2016
- 14
Grants received
2024–2027 · grant · PRMRP
Omniphobic Cerebral Shunt to Eliminate Clogging and Dysfunction
Todd Mcfarland · Cerulean Pharma (United States) · funded by Congressionally Directed Medical Research Programs
2024–2025 · research · R44
Slippery, Omniphobic Coating to Prevent Thrombosis and Biofilm Formation on Peripheral Vascular Grafts
Todd Mcfarland · Cerulean Pharma (United States) · funded by National Institutes of Health
2024–2027 · research · R44
Slippery, Omniphobic Coating to Prevent Thrombosis and Biofilm Formation on Peripheral Vascular Grafts
Todd Mcfarland · Cerulean Pharma (United States) · funded by National Institutes of Health
2023–2026 · research · R44
Slippery Omniphobic Coating for Hemodialysis Catheter to Resist Fibrin Sheathing and Infection and Improve Patient Outcomes
Todd Mcfarland · Cerulean Pharma (United States) · funded by National Institutes of Health
2023–2026 · research · R44
Slippery Omniphobic Coating for Hemodialysis Catheter to Resist Fibrin Sheathing and Infection and Improve Patient Outcomes
Todd Mcfarland · Cerulean Pharma (United States) · funded by National Institutes of Health
2023–2027 · research · R44
Slippery Omniphobic Coating for Hemodialysis Catheter to Resist Fibrin Sheathing and Infection and Improve Patient Outcomes
Todd Mcfarland · Cerulean Pharma (United States) · funded by National Institutes of Health
2022–2023 · research · R43
Tethered liquid perfluorocarbon coating for preventing urinary catheter colonization
Todd Mcfarland · Cerulean Pharma (United States) · funded by National Institutes of Health
2021–2022 · research · R43
Omniphobic Coating of Extracorporeal Life Support Systems for Improved Thromboresistance
Saibal Bandyopadhyay · Cerulean Pharma (United States) · funded by National Institutes of Health
2019–2021 · research · R43
Slippery Omniphobic Coating for Hemodialysis Catheter to Improve Patency and Patient Outcomes
Saibal Bandyopadhyay · Cerulean Pharma (United States) · funded by National Institutes of Health
2018–2023 · research · R42
Omniphobic cerebral shunt to eliminate clogging and dysfunction
Saibal Bandyopadhyay · Cerulean Pharma (United States) · funded by National Institutes of Health
2018–2019 · research · R43
Omniphobic Coating to Prevent Central Line Catheter Infections
Andrew K Jones · Cerulean Pharma (United States) · funded by National Institutes of Health
2018–2020 · research · R41
Inert Coating for Cerebral Shunts to Eliminate Clogging
Andrew K Jones · Cerulean Pharma (United States) · funded by National Institutes of Health
2018–2024 · research · R42
Omniphobic Cerebral Shunt to Eliminate Clogging and Dysfunction
Carolyn A Harris · Cerulean Pharma (United States) · funded by National Institutes of Health
2018–2023 · research · R42
Omniphobic cerebral shunt to eliminate clogging and dysfunction
Saibal Bandyopadhyay · Cerulean Pharma (United States) · funded by National Institutes of Health